Home » Stocks » BIO

Bio-Rad Laboratories, Inc. (BIO)

Stock Price: $608.01 USD 5.84 (0.97%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 18.19B
Revenue (ttm) 2.70B
Net Income (ttm) 4.10B
Shares Out 29.82M
EPS (ttm) 135.87
PE Ratio 4.47
Forward PE 47.62
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $608.01
Previous Close $602.17
Change ($) 5.84
Change (%) 0.97%
Day's Open 607.05
Day's Range 603.68 - 615.32
Day's Volume 137,872
52-Week Range 425.43 - 689.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Bio-Rad's (BIO) first-quarter revenues improved year over year on robust growth in Life Science and Clinical Diagnostics segments.

1 week ago - Zacks Investment Research

Bio-Rad (BIO) delivered earnings and revenue surprises of 108.40% and 9.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the f...

1 week ago - Business Wire

Growing demand for Polymerase Chain Reaction and Droplet Digital PCR products is expected to have contributed to BioRad's (BIO) Q1 growth.

1 week ago - Zacks Investment Research

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first...

3 weeks ago - Business Wire

In my opinion, investors could be interested in the three stocks listed below, as they meet the following criteria:

Other stocks mentioned: KB, WGO
3 weeks ago - GuruFocus

We have narrowed down our search to the following stocks, FLGT, BIO and IDXX based on a favorable Zacks Rank and strong prospects for 2021.

Other stocks mentioned: ABT, BDX, DGX, FLGT, IDXX
1 month ago - Zacks Investment Research

Other stocks mentioned: INVA, SAGE
1 month ago - GuruFocus

Investors remain optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies and robust testing portfolio.

1 month ago - Zacks Investment Research

Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Benjamin Graham, the father of value investing, recommended to stick to stocks that have a current ratio of more than 2 and more working capital than long-term debt.

Other stocks mentioned: BCPC, RETA
1 month ago - GuruFocus

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, Presi...

2 months ago - Business Wire

Non-operating income not only overstates GAAP net income but could negatively impact Bio-Rad's ability to obtain additional financing.

2 months ago - Forbes

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, Presi...

2 months ago - Business Wire

Does Bio-Rad Laboratories (BIO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Other stocks mentioned: RAD
2 months ago - Zacks Investment Research

Bio-Rad's (BIO) fourth-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.

2 months ago - Zacks Investment Research

Bio-Rad (BIO) delivered earnings and revenue surprises of 29.35% and 15.85%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Bio-Rad Laboratories (NYSE:BIO) moved higher by 2.0% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 72.84% year over year to $4.0...

2 months ago - Benzinga

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the f...

2 months ago - Business Wire

Bio-Rad Laboratories (NYSE:BIO) unveils its next round of earnings this Thursday, February 11. Get prepared with Benzinga's ultimate preview for Bio-Rad Laboratories's Q4 earnings.

2 months ago - Benzinga

Bio-Rad (BIO) Q4 earnings are expected to have benefited from strong sales, particularly within core PCR products, Droplet Digital PCR and Process Media.

3 months ago - Zacks Investment Research

These are the stocks with the best value, fastest growth, and most momentum for February.

Other stocks mentioned: AGCO, BDN, BPYU, ENPH, MRNA, NLOK, NRG ...
3 months ago - Investopedia

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the fourt...

3 months ago - Business Wire

These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.

Other stocks mentioned: BIIB, CVS, HZNP, MRNA, PODD, QDEL, TDOC
3 months ago - Investopedia

If you pick securities whose earnings return is more than twice that of the 20-year high-quality market corporate bonds, you could increase your probability to unearth value opportunities, in my opinion...

Other stocks mentioned: FVE, SUPN
3 months ago - GuruFocus

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, Presi...

4 months ago - Business Wire

"Why do you like tobacco stocks so much?" my colleague asked our boss, David Dreman (Trades, Portfolio), about two decades ago.

Other stocks mentioned: AEL, CNNE, FF, IMKTA, REGI, UNM, WOR ...
4 months ago - GuruFocus

These are the healthcare stocks with the best value, fastest growth, and most momentum for January 2021.

Other stocks mentioned: BIIB, CVS, HZNP, MRNA, PODD, QDEL, XLRN ...
4 months ago - Investopedia

Perhaps you've seen the Energizer Bunny in a battery commercial. It is "still going" long after you'd expect it to fade.

Other stocks mentioned: EQC, FFWM, LGIH, MSBF, MSGN, PFSI
4 months ago - GuruFocus

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today its outlook through 2023, w...

4 months ago - Business Wire

Investors continue to be optimistic about Bio-Rad (BIO) on robust growth of the Life Science segment and a solid testing portfolio.

5 months ago - Zacks Investment Research

These are the healthcare stocks with the best value, fastest growth, and most momentum for December 2020.

Other stocks mentioned: PODD, XLV, MRNA
5 months ago - Investopedia

Is (BIO) Outperforming Other Medical Stocks This Year?

5 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for November 13th

Other stocks mentioned: PLT, SSTK, THRM
5 months ago - Zacks Investment Research

Value focused investors may want to consider the following stocks, since their share prices are trading at a discount to the intrinsic value calculated by GuruFocus' earnings-based discounted cash flow ...

Other stocks mentioned: BK, GLIBA
5 months ago - GuruFocus

As of late, it has definitely been a great time to be an investor in Bio-Rad Laboratories (BIO).

5 months ago - Zacks Investment Research

Bio-Rad (BIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

6 months ago - Zacks Investment Research

Bio-Rad's (BIO) third-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.

6 months ago - Zacks Investment Research

Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Bio-Rad (BIO) delivered earnings and revenue surprises of 62.16% and 14.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Shares of Bio-Rad Laboratories (NYSE:BIO) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 86.34% year over year to $3.00, which beat th...

6 months ago - Benzinga

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the t...

6 months ago - Business Wire

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in r...

6 months ago - Insider Monkey

Bio-Rad (BIO) Q3 earnings are expected to have benefited from strong sales particularly within core PCR products, Droplet Digital PCR and Process Media.

6 months ago - Zacks Investment Research

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Bio-Rad Gains 16.2% Since September, Bullish Outlook Remains Strong

6 months ago - Seeking Alpha

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the third...

6 months ago - Business Wire

Bio-Rad (BIO) is optimistic about maintaining robust testing portfolio along with strength in its Life Sciences business.

6 months ago - Zacks Investment Research

With four potential Covid-19 vaccine candidates from Moderna Inc. (NASDAQ:MRNA), Pfizer Inc. (NYSE:PFE), AstraZeneca PLC (NYSE:AZN) and Johnson & Johnson (NYSE:JNJ) now in late-stage human trials, and m...

Other stocks mentioned: DVA, MOH
7 months ago - GuruFocus

About BIO

Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research tech... [Read more...]

Industry
Medical Devices
Founded
1952
CEO
Norman Schwartz
Employees
7,800
Stock Exchange
NYSE
Ticker Symbol
BIO
Full Company Profile

Financial Performance

In 2020, BIO's revenue was $2.55 billion, an increase of 10.12% compared to the previous year's $2.31 billion. Earnings were $3.81 billion, an increase of 116.43%.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for BIO stock is "Buy." The 12-month stock price forecast is 755.00, which is an increase of 24.18% from the latest price.

Price Target
$755.00
(24.18% upside)
Analyst Consensus: Buy